Replies to post #2443 on Synaptogenix Inc (SNPX)

[donsker]

Whether the success ratio is 80%, 50% or something else, it matters little. This is a new approach that has had positive results in animal testing and compassionate use. The science seems strong. I think we all assume the data will be positive, just a question of how positive. If you want to just keep it on a binary basis, the odds are 50-50. Look at the price action. Even with manipulation there's a steady floor at $19.00, with little volume. No wild swings down. I think Neurotrope has executed well. My only question, any news on the uplifting to NASDAQ. My talk with the IR last week, he said he wasn't sure. Anything new?

[Whatsupp]

"Don't have any human clinical data on efficacy. In fact, Neurotrope pr said there were no sign of cognitive improvement"

That is not what Dr Alkon said at the Oppenheimer presentation. Go to minute 22 and hear what he said about the 2a study. Essentially that they saw measurable improvements in the treated patients compared to the Placebo group after 1 treatment within 3 hours.

I agree that 80% is an optimistic estimate of success, but I believe even if the 2b data dose not show a homerun, there will be data that will provide a path to a successful treatment, aka a singe or a double.